-
Defending champ Shelton finding tournament sweet spot in Montreal
-
Osaka out to improve Toronto fortunes with eye on US Open
-
Democratic-led US states sue in latest challenge to Trump's tariffs
-
Dow hits fresh record as oil prices tumble
-
Trump says Iran facing 'last chance before decapitation'
-
Trump board reassures Israel after objections on Gaza pullout
-
US northwest battles wildfires after Spokane neighborhoods scorched
-
Zelensky sacks his ambassador to the US
-
Iran denies negotiating with US, drawing Trump backlash
-
'Spider-Man' breaks record for domestic box office debut
-
Key dates for the Boeing 737 MAX
-
US regulators grant long-awaited Boeing 737 MAX 7 certificate
-
Israel objects to US-backed Gaza plan, defiant on pullout
-
Eala powers past Pegula for first WTA title in Washington
-
Norway's Haugset wins stage 3 to claim Tour de France Femmes lead
-
Legionnaires' outbreak in Switzerland's Basel kills one, 26 ill
-
Cuba slowly regains power after latest nationwide blackout
-
Infantino, the FIFA president under pressure after scrapped investor plan
-
Chelsea sign England midfielder Jordan Henderson
-
Young Danes start extended military service
-
Wildfire flares up again in Greece as water bombers deployed
-
England, Wales had driest July on record: Met Office
-
Greece wildfire expert says season 'one of the worst' in a decade
-
French court rejects pro-Kremlin commentator's deportation appeal
-
Sandoz strikes US settlements to resolve generic drug price dispute
-
Oil slides, stocks rise on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan, keeps up strikes on territory
-
EU chief urges 'united action' on borders after Ceuta migrant rush
-
Inside Capital Regency's Market Expansion and User Acquisition
-
Oil prices slide on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan and keeps striking
-
Dortmund sign Greek teenager Karetsas from Genk
-
Bangladesh measles outbreak drives families into debt: aid groups
-
Detained Aung San Suu Kyi meets Red Cross delegate in Myanmar
-
BitMart、説明を迫られる:SNC SCANDIC COINの出金は8日経っても依然としてTXIDなし
-
설명 압박에 직면한 BitMart: 8일이 지나도 여전히 TXID가 없는 SNC SCANDIC COIN 출금
-
Seoul issues first 'severe heatwave warning' under new system
-
BitMart تحت ضغط لتقديم توضيحات: عمليات سحب عملة SNC SCANDIC COIN لا تزال بدون معرّف المعاملة (TXID) بعد مرور ثمانية أيام
-
BitMart змушений надати пояснення: виплати в SNC SCANDIC COIN через вісім днів досі без TXID
-
Welsh FA withdraws support for Infantino's FIFA re-election bid
-
BitMart 面臨解釋壓力:SNC SCANDIC COIN 提現八天後仍無 TXID
-
BitMart under pressure to explain: SNC SCANDIC COIN withdrawals still without a TXID after eight days
-
Cycling superstar Pogacar to ride in Vuelta
-
Iran denies negotiating with US after Trump announces talks
-
Water bombers take to skies as Greece battles wildfires
-
What Europe can learn from Australia's 'Black Summer' wildfires
-
Training the UK 'surgeons of the future' using robots
-
Oil prices sink on Iran hopes, yen gains after joint intervention
-
US, Japan join forces to boost yen
-
Wildfires raze neighborhoods in US northwest city of Spokane
US medical agency will scale back testing on monkeys
The United States will scale back certain drug-safety testing requirements on monkeys, federal regulators said Tuesday, marking the latest step by President Donald Trump's administration to limit the use of animals in research.
Under new draft guidance from the Food and Drug Administration, computer models, lab-grown mini-organs, and human studies will replace the use of non-human primates in testing monoclonal antibodies -- lab-engineered proteins used to treat cancers, autoimmune conditions and other diseases.
"We are delivering on our roadmap commitment to eliminate animal testing requirements in drug evaluation and our promise to accelerate cures and meaningful treatments for Americans," FDA Commissioner Marty Makary said in a statement.
The statement added that typical nonclinical programs involving monoclonal antibodies could include more than 100 macaque monkeys -- apes are no longer used in any invasive research in the US -- yet often do not yield human-approved treatments.
The move was welcomed by animal-advocacy groups.
Zaher Nahle, a former animal researcher who is now the senior scientific advisor for nonprofit Center for a Humane Economy, told AFP the move was an "important step."
"These primates are not reliable in terms of predicting the toxicity, so you can get at least equal or better results in terms of your accuracy in predicting toxicology using other approaches," he added.
What's more, he noted, studies show that more than 90 percent of drugs deemed safe and effective in animals fail to win approval for human use.
The FDA's announcement follows a report in the journal Science last month that the Centers for Disease Control and Prevention would close its primate labs.
It "moves us one step closer to wiping out the federal government's wasteful monkey business," Justin Goodman of White Coat Waste Project told AFP.
But the National Institutes of Health -- the country's primary biomedical research agency -- remains a notable "outlier," he added. According to public data, 7,700 primates are confined in federal government labs and breeding facilities, of which 6,700 are at NIH.
Advocates of animal research have pushed back.
"Poorly planned transitions -- including premature study termination -- can place animals at serious risk and may undermine years of scientific investment intended to strengthen public health preparedness and advance lifesaving medical progress," advocacy group Americans for Medical Progress said after the CDC news was reported.
Proponents of animal testing say the research has been indispensable for major medical advances, including vaccines for diphtheria, yellow fever, measles and Covid-19.
Critics counter that decades-old laws have created regulatory lock-in, that publication incentives reward animal studies in top journals, and that a lucrative "animal-industrial complex" has helped entrench the status quo.
D.Schneider--BTB